Beranda › Kanker Paru › New York

Uji klinis Kanker Paru di New York

93 studi untuk Kanker Paru mencari peserta di lokasi di New York.

Kota di New York

Teks studi resmi (Bahasa Inggris)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Northwell Health Imbert Cancer Center, Bay Shore
Maimonides Medical Center, Brooklyn
Roswell Park Cancer Institute, Buffalo
dan 18 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04267848

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity), Commack
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
dan 1 lainnya

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04991025

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Columbia University Medical Center, New York
Memorial Sloan Kettering, New York

Menerima pesertaFase 1/2

Usia 12 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04585750

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Queens Hospital Center, Jamaica
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Stony Brook University Medical Center, Stony Brook

Menerima pesertaStudi observasionalSukarelawan sehat diterima

Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Roswell Park Cancer Institute IDS, Buffalo
Memorial Sloan Kettering Hospital, New York

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06172478

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Glens Falls Hospital, Glens Falls
Upstate Cancer Center at Oswego, Oswego
University of Rochester, Rochester
dan 7 lainnya

Menerima pesertaFase 3

Usia 70 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06096844

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
The Cancer Institute at Saint Francis Hospital, East Hills
dan 13 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT04181060

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Columbia University Irving Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06625775

Empathic Communication Skills (ECS) Training

Roswell Park Cancer Institute (Data Collection Only), Buffalo
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

Menerima pesertaSukarelawan sehat diterima

Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05456841

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Montefiore Medical Center-Einstein Campus, The Bronx
Montefiore Medical Center-Weiler Hospital, The Bronx
Montefiore Medical Center - Moses Campus, The Bronx
dan 1 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06498635

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NYU Langone's Perlmutter Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Optum Medical Care, PC, Westbury

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06765109

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Cancer Center, New York
Montefiore Medical Center, The Bronx

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06881784

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

MSK Commack, Commack
MSK Westchester, East White Plains
Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy, Long Island City
dan 3 lainnya

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07476287

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

GSK Investigational Site, East Syracuse

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07099898

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Cayuga Medical Center ( Site 0086), Ithaca
University Hospital at Stony Brook ( Site 0054), Stony Brook
White Plains Hospital ( Site 0091), White Plains

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06312137

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

New York Oncology Hematology, Albany
New York Oncology Hematology, Clifton Park
Hematology Oncology Associates of Rockland, Nyack

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07222566

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Hematology Oncology Associates of Rockland, Nyack

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06758401

A Registry for People With Lung Cancer

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
dan 1 lainnya

Menerima pesertaStudi observasional

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06424327

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

WMCHealth Advanced Physician Services, Hawthorne
Local Institution - 0128, Rochester
Local Institution - 0518, Schenectady

Menerima pesertaFase 2/3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07063745

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Buffalo

Menerima pesertaFase 2

Usia 18 hingga 95 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT05061550

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Nuvance Health, Poughkeepsie
Suny-Stony Brook University Cancer Center, Stony Brook
White Plains Hospital, White Plains

Menerima pesertaFase 2/3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06712316

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Columbia University, New York
NYU Langone Health, New York
Memorial Sloan Kettering Cancer Center, New York

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06128551

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
NYU Langone Health, New York
Weill Cornell Medical College, New York
dan 1 lainnya

Menerima pesertaFase 2/3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07100080

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

NYU Langone Health Perlmutter Cancer Center, New York

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07629960

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07349537

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Memorial Sloan Kettering Cancer Center, New York

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06287775

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
Memorial Sloan Kettering Cancer Center, New York

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT05786924

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

NYU Langone Hospital - Long Island Investigational Pharmacy, Mineola
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06293898

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

SUNY Upstate Medical University, Syracuse
Montefiore Einstein Cancer Center, The Bronx
Clinical Research Alliance, Westbury

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06793215

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Maimonides Cancer Center, Brooklyn
Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success
Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
dan 3 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06561685

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

NYU Langone Health - Long Island, Mineola
New York University (NYU) Clinical Cancer Center, New York
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06400472

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Avenzo Therapeutics Recruiting Site, New York

Menerima pesertaFase 1/2

Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07038343

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Roswell Park Cancer Institute, Buffalo
Perlmutter Cancer Center - NYU Langone Health, New York
Memorial Sloan Kettering Cancer Center, New York

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06343402

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Northwell Health/R.J. Zuckerberg Cancer Center, Lake Success
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07185997

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Cornell University - NewYork-Presbyterian/Weill Cornell Medical Center, New York
White Plains Hospital, White Plains

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06712355

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

New York Cancer & Blood Specialists, New York
University of Rochester - Wilmot Cancer Institute, Rochester

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT06582017

Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer

Roswell Park Cancer Institute, Buffalo

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT07718672

Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer

Roswell Park Cancer Institute, Buffalo

Menerima peserta

Usia 21 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT05787834

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

Roswell Park Cancer Institute, Buffalo

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT07017829

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.